This mechanism was observed in each immunophenotypic category of LGL leukemia patients, in detail, both STAT3 mutated patients and wild type patients, presenting different P-STAT3 and Fas ligand levels, showed similar molecular responses to IL-6 or IL-15 activation and Stattic inhibition. This evidence concerns the gene IL6 and T-cell large granular lymphocyte leukemia.